Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Grant revenue	$ 0	$ 0	$ 0	$ 81,526
Operating expenses:
Research and development	6,947,979	2,721,196	14,486,896	5,358,917
General and administrative	1,651,775	1,249,337	4,562,293	3,363,672
Total operating expenses	8,599,754	3,970,533	19,049,189	8,722,589
Loss from operations	(8,599,754)	(3,970,533)	(19,049,189)	(8,641,063)
Other income:
Interest income	190,936	2,431	674,835	3,747
Net loss	$ (8,408,818)	$ (3,968,102)	$ (18,374,354)	$ (8,637,316)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.32)	$ (0.17)	$ (0.69)	$ (0.63)
Weighted average shares outstanding (in shares)	26,544,058	23,461,665	26,442,847	13,818,315